Dr. Carsten Brockmeyer, PhD, is an independent expert and pioneer in the development of biopharmaceutical and biosimilar medicinal products. He has served from 1991 to 1998 as scientific group leader and then science director at Baxter International, with responsibilities including the development and quality control of various monoclonal antibodies. In 1998 he took a position as project manager for biotechnology at Hexal AG. He was in 1999 appointed general manager of HEXAL Biotech Forschung GmbH, where he oversaw the development of the first-ever biosimilar for epoetin alpha and for biosimilar filgrastim. Afterwards Dr. Brockmeyer became head of global project management at Sandoz Biopharmaceuticals, where he continued to direct the development of important biosimilars development projects at HEXAL/Sandoz. In recent years, he has advised clients through his own consulting company, Brockmeyer Biopharma. He is the author of more than 100 scientific publications and credited with a number of patented inventions. His acclaimed work in the field of biopharmaceuticals has been recognized with prestigious scientific awards. In 2015 and 2016 Carsten Brockmeyer has been ranked repeatedly among the 100 most influential people across the globe in the field of medicine by the journal „The Medicine Maker“.